New report reveals programs that promote healthy ageing can help reduce rising health costs1
10 October 2012 | By Pfizer
In 2050, the number of people aged 60+ years worldwide will increase to nearly 2 billion...
List view / Grid view
10 October 2012 | By Pfizer
In 2050, the number of people aged 60+ years worldwide will increase to nearly 2 billion...
9 October 2012 | By GlaxoSmithKline
GSK welcomes the announcement from GAVI Alliance...
9 October 2012 | By Merck
Merck has announced plans to move the company's global headquarters within the state...
9 October 2012 | By Sanofi
Sanofi announced the launch by Sanofi India Limited of AllStar™...
9 October 2012 | By Genzyme
New data from Genzyme’s clinical development programs...
8 October 2012 | By Azbil BioVigilant
Leiter Rx will utilize Azbil BioVigilant’s IMD-A® 300-series systems...
Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that detailed results from the pivotal Phase III VELOUR study evaluating ZALTRAP® (aflibercept) Injection for Intravenous Infusion for the treatment of patients with previously treated metastatic colorectal cancer were published in the October 2012 edition of the Journal of Clinical Oncology (JCO).
8 October 2012 | By AstraZeneca
AstraZeneca and Ardelyx announced a worldwide exclusive licensing agreement for Ardelyx’s NHE3 inhibitor programme...
8 October 2012 | By Teva Pharmaceutical Industries Ltd
Key data from the Company’s MS franchise...
5 October 2012 | By Sanofi
New data from ORIGIN shows Lantus® use is about 3 times more likely to achieve and sustain target HbA1c vs. standard care over 5 years in the study population...
5 October 2012 | By Novo Nordisk
4/5 people with type 2 diabetes have experienced self-treated hypoglycaemia...
4 October 2012 | By Boehringer Ingelheim
New data from HCVersoTM have been accepted for presentation...
4 October 2012 | By GlaxoSmithKline
Dolutegravir is not yet approved as a treatment for HIV...
4 October 2012 | By Pfizer
Pfizer has announced top-line data...
3 October 2012 | By Merck
Phase III trials of MK-3102 underway...